Dilution Tracker

Below will be a frequently updated table of companies cash position and date of last dilution.  As all biotech traders know, emerging biotechs often have to raise cash to support the cost of trials, drug development and regulatory activities.  Many of these companies will do multiple share offerings before a drug is a approved and can generate cash flow via product revenues/royalties. 

So before buying into any stock, part of your DD should be to check for cash on hand as of last 10-Q, cash burn rate, and date of last capital raise (typically selling a fixed amount of shares at a pre-determined price, thus diluting the stock price)

XOMA: Gevokizumab phase 3 EYEGUARD-B study, the objective of the first part of this study is to demonstrate the superiority of gevokizumab, as compared to placebo, on top of the current standard of care (immunosuppressant therapy and oral corticosteroids) in reducing the risk of Behçet's disease uveitis exacerbations and to assess the safety of gevokizumab.

 

Stock	*Cash-on-Hand	Last dilution/ATM	Catalyst:	**OS
XOMA	67.5m	40m  12/9/14	See above	117.82m

Likely will need to raise cash by end of 2015 to support 2016 activities.

* Cash on hand as of last Quarterly update
**OS = Outstanding stocks updated from Google Finance as of last update date below.
Updated as of 6/4/2015
m= millions

MEIP: Data from the open-label Phase II study of Pracinostat in combination with azacitidine in elderly patients with newly diagnosed AML in December 2014.for prasinostat in AML will be presented in June during the annual EHS conference.  

Stock	*Cash-on-Hand	Last dilution/ATM	Catalyst:	**OS
MEIP	70.5m	46m  12/7/14	See above	34.6m

* Cash on hand as of last Quarterly update
**OS = Outstanding stocks updated from Google Finance as of last update date below.
Updated as of 6/4/2015
m= millions